News | January 9, 2025

Biofidelity And Cellcarta Partner To Deploy Aspyre® Lung In Global Clinical Trials

Cambridge and Montreal, QC /PRNewswire/ - Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical companies seeking precision medicine solutions, today announced a strategic partnership agreement to utilize Biofidelity's Aspyre® Lung in global clinical trials.

Source: Biofidelity

Copyright 2025 PR Newswire. All Rights Reserved